Literature DB >> 15023152

De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years?

Salvador Benlloch1, Marina Berenguer, Martín Prieto, Rosalba Moreno, Fernando San Juan, Miguel Rayón, Jose Mir, Angel Segura, Joaquín Berenguer.   

Abstract

The goal of the study was to determine the incidence and variables associated with post-liver transplantation (LT) de novo internal neoplasms development, excluding skin tumors and hepatocellular carcinoma. Medical records were reviewed for recipient/donor demographics, viral serology, cause of liver disease, interval from LT to tumor diagnosis, predisposing factors, immunosuppression and survival. Forty-one neoplasms (31 solid and 10 hematologic) developed in 772 recipients (5.3%) transplanted between 1991 and 2001. Time to tumor diagnosis was longer in patients transplanted before 1995 than in those transplanted afterwards (58 vs. 22 months; p<0.05). Hematologic neoplasms (HN) appeared earlier than solid (2 vs. 21 months; p<0.001), were more prevalent in those transplanted after 1995 than before (32% vs. 12.5%), and had lower survival than solid (2 vs. 21 months, p<0.001). While HCV was the most frequent indication in HN (70%), alcohol was that of solid tumors (71%). Overall, risk factors for de novo neoplasms included alcohol and immunosuppression (p<0.01). In patients undergoing LT in recent years, there is a higher incidence of HN with de novo internal neoplasms developing at earlier time-points than in those transplanted years ago. Risk factors for tumor development include alcohol, HCV and possibly strong immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023152     DOI: 10.1111/j.1600-6143.2004.00380.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  29 in total

Review 1.  Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression management.

Authors:  Christophe Carenco; Stéphanie Faure; José Ursic-Bedoya; Astrid Herrero; Georges Philippe Pageaux
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 2.  Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence.

Authors:  Shirin Elizabeth Khorsandi; Nigel Heaton
Journal:  Transl Gastroenterol Hepatol       Date:  2016-04-06

3.  De novo malignancy post-liver transplantation: a single center, population controlled study.

Authors:  Hemant Chatrath; Kenneth Berman; Raj Vuppalanchi; James Slaven; Paul Kwo; A Joseph Tector; Naga Chalasani; Marwan Ghabril
Journal:  Clin Transplant       Date:  2013-06-30       Impact factor: 2.863

Review 4.  Long-term survival after liver transplantation for alcoholic liver disease.

Authors:  Paula Iruzubieta; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

5.  Evolution and management of de novo neoplasm post-liver transplantation: a 20-year experience from a single European centre.

Authors:  Gonzalo Sapisochin; Itxarone Bilbao; Cristina Dopazo; Luis Castells; Jose Luis Lázaro; Roberto Rodríguez; Mireia Caralt; Laia Blanco; Joaquin Balsells; Ramón Charco
Journal:  Hepatol Int       Date:  2010-12-28       Impact factor: 6.047

6.  Case report: Bone tumor of the scapula in a patient undergoing liver transplantation.

Authors:  Zhen-Qi Ding; Hai-Fang Zhang; Liang-Qi Kang; Mo Sha
Journal:  Clin Orthop Relat Res       Date:  2012-01-04       Impact factor: 4.176

7.  Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis.

Authors:  Mohamad A Mouchli; Siddharth Singh; Edward V Loftus; Lisa Boardman; Jayant Talwalkar; Charles B Rosen; Julie K Heimbach; Russell H Wiesner; Bashar Hasan; John J Poterucha; Watt D Kymberly
Journal:  Transplantation       Date:  2017-08       Impact factor: 4.939

Review 8.  Keys to long-term care of the liver transplant recipient.

Authors:  Kymberly D Watt
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-13       Impact factor: 46.802

Review 9.  Incidence, risk factors and outcomes of de novo malignancies post liver transplantation.

Authors:  Pavan Kedar Mukthinuthalapati; Raghavender Gotur; Marwan Ghabril
Journal:  World J Hepatol       Date:  2016-04-28

Review 10.  Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?

Authors:  Jan Lerut; Samuele Iesari; Maxime Foguenne; Quirino Lai
Journal:  Transl Gastroenterol Hepatol       Date:  2017-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.